Results 271 to 280 of about 54,594 (319)

Additive efficacy of a bispecific anti–TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis

Science Translational Medicine, 2023
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases affecting primarily the joints. Despite successful therapies including antibodies against tumor necrosis factor (TNF) and interleukin-6 (IL-6) receptor, only 20 to 30% of patients ...
Nadine Biesemann, D. Margerie, C. Asbrand, Markus Rehberg, Virginia Savova, I. Agueusop, Daniel Klemmer, D. Ding-Pfennigdorff, U. Schwahn, Markus Dudek, K. Heyninck, Evelyn De Tavernier, S. Cornelis, M. Kohlmann, F. Nestle, M. Herrmann   +15 more
semanticscholar   +1 more source

Bispecific Antibodies in Lymphoma

International Reviews of Immunology, 1993
Journal Article ; Review ; SCOPUS: ar.j ; info:eu-repo/semantics ...
Brissinck, J, Demanet, Christian, Moser, Muriel, Leo, Oberdan, Thielemans, Kris   +4 more
openaire   +2 more sources

Production of Bispecific Antibodies

Current Protocols in Immunology, 1995
AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire   +2 more sources

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.

Blood
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens.
Gilles Crochet, G. Iacoboni, Audrey Couturier, E. Bachy, J. Iraola-Truchuelo, T. Gastinne, G. Cartron, Tom Fradon, B. Lesne, Mi Kwon, Romain Gounot, N. Martínez-Cibrian, C. Castilla-Llorente, P. Abrisqueta, M. Guerreiro, C. Sarkozy, J. Aspa-Cilleruelo, V. Camus, S. Guidez, A. Chauchet, Eric Deconinck, K. Bouabdallah, Francesc Bosch, P. Barba, Franck Morschhauser, R. Houot   +25 more
semanticscholar   +1 more source

Bispecific antibodies in the treatment of multiple myeloma

Blood Cancer Journal
The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal antibodies like daratumumab along with proteasome inhibitors (PI)s, and immune modulators (IMiD)s have significantly improved survival and outcomes, but also cause unique
A. Devasia, A. Chari, Guido Lancman
semanticscholar   +1 more source

Fine-tuning bispecific therapeutics

Pharmacology & Therapeutics, 2020
Bispecific therapeutics target two distinct antigens simultaneously and provide novel functionalities that are not attainable with single monospecific molecules or combinations of them. The unique potential of bispecific therapeutics is driving extensive efforts to discover synergistic dual targets, design molecular formats to integrate bispecific ...
openaire   +2 more sources

Bispecific antibodies rise again

Nature Reviews Drug Discovery, 2014
Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems.
openaire   +2 more sources

Bispecific antibodies.

Critical reviews in immunology, 1993
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire   +1 more source

Immunotherapeutic perspective for bispecific antibodies

Immunology Today, 2000
Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
A B, van Spriel, H H, van Ojik, J G, van De Winkel   +2 more
openaire   +2 more sources

Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies

2019
Bispecific antibodies are an emerging novel therapeutic construct used to treat a variety of cancers. These drugs utilize a small fusion protein to link two single-chain antibodies, allowing for simultaneous binding of two different epitopes. Bispecific T-cell engagers (BiTE) are a subset of bispecific antibodies that bind the target antigen on the ...
Stacy L. Cooper, Patrick A. Brown
openaire   +1 more source